Immunovant, Inc. (NASDAQ:IMVT) Stock Has Average Target Price of $44.60 According to Brokerages

Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have earned an average rating of “Moderate Buy” from the thirteen ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $44.60.

Several equities research analysts have recently issued reports on the stock. Truist Financial raised their price objective on shares of Immunovant from $30.00 to $33.00 and gave the stock a “hold” rating in a research note on Tuesday, November 10th. Wall Street Zen upgraded shares of Immunovant from a “sell” rating to a “hold” rating in a research note on Saturday, November 14th. Wells Fargo & Company upped their target price on shares of Immunovant from $45.00 to $47.00 and gave the company an “overweight” rating in a research note on Tuesday, November 10th. Citigroup reissued a “positive” rating on shares of Immunovant in a report on Thursday, September 24th. Finally, UBS Group restated a “buy” rating on shares of Immunovant in a research report on Wednesday, September 23rd.

Get Our Latest Report on IMVT

Immunovant Stock Down 2.3%

IMVT opened at $31.77 on Thursday. The stock’s 50 day moving average price is $32.06 and its two-hundred day moving average price is $32.50. The firm has a market capitalization of $6.57 billion, a P/E ratio of -12.41 and a beta of 0.95. Immunovant has a 12-month low of $21.86 and a 12-month high of $45.42.

Immunovant (NASDAQ:IMVT – Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.27. During the same period last year, the business earned ($0.73) EPS. As a group, analysts anticipate that Immunovant will post -2.49 earnings per share for the current year.

Insider Buying and Selling at Immunovant

In related news, CEO Eric Venker sold 3,506 shares of the stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $34.11, for a total value of $119,589.66. Following the completion of the sale, the chief executive officer owned 257,075 shares in the company, valued at approximately $8,768,828.25. This trade represents a 1.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Christopher Van Tuyl sold 2,846 shares of Immunovant stock in a transaction dated Wednesday, September 23rd. The stock was sold at an average price of $36.36, for a total value of $103,480.56. Following the sale, the insider directly owned 176,545 shares in the company, valued at approximately $6,419,176.20. This trade represents a 1.59% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 27,430 shares of company stock valued at $895,852 in the last three months. Company insiders own 1.90% of the company’s stock.

Hedge Funds Weigh In On Immunovant

Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Immunovant in the 2nd quarter worth approximately $276,680,000. Two Seas Capital LP grew its holdings in shares of Immunovant by 46.5% during the 3rd quarter. Two Seas Capital LP now owns 4,612,692 shares of the company’s stock worth $155,817,000 after purchasing an additional 1,464,187 shares in the last quarter. ADAR1 Capital Management LLC grew its holdings in shares of Immunovant by 8.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 2,679,010 shares of the company’s stock worth $66,547,000 after purchasing an additional 198,042 shares in the last quarter. Bank of America Corp DE bought a new stake in shares of Immunovant during the second quarter valued at approximately $45,521,000. Finally, Aberdeen Group plc increased its position in shares of Immunovant by 2.6% during the third quarter. Aberdeen Group plc now owns 879,334 shares of the company’s stock valued at $29,704,000 after purchasing an additional 22,304 shares during the period. Institutional investors and hedge funds own 47.08% of the company’s stock.

Immunovant Company Profile

(Get Free Report)

Immunovant, Inc. is a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases. Its research focuses on inhibiting the neonatal Fc receptor (FcRn), a pathway involved in maintaining levels of disease-causing antibodies. The company’s investigational medicines include batoclimab and IMVT-1402, both designed to reduce circulating antibodies. Immunovant has studied or evaluated these candidates for conditions including myasthenia gravis, Graves’ disease and other autoimmune disorders.

See Also

Analyst Recommendations for Immunovant (NASDAQ:IMVT)

Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.